Analysis of the Results of Tuberculosis Drug Resistance Surveillance in Yuexiu District, Guangzhou City, 2013–2022

IF 3.1 4区医学 Q3 IMMUNOLOGY

Immunity, Inflammation and Disease Pub Date : 2024-11-27 DOI:10.1002/iid3.70060

Xueqiu Li, Jianxiong Liu

{"title":"Analysis of the Results of Tuberculosis Drug Resistance Surveillance in Yuexiu District, Guangzhou City, 2013–2022","authors":"Xueqiu Li, Jianxiong Liu","doi":"10.1002/iid3.70060","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The objectives of the study are to understand the drug-resistant situation and trend of tuberculosis patients in Yuexiu District, Guangzhou City, from 2013 to 2022, and to provide a scientific basis for the development of rational drug-resistant tuberculosis prevention and control strategies in Guangzhou City.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>All patients who were diagnosed with active tuberculosis in Guangzhou Chest Hospital from January 1, 2013 to December 31, 2022 were collected as study subjects, and a total of 5191 patients were enrolled in the study. Comprehensive data on the basic characteristics, diagnostic, and therapeutic information of the study subjects were collected. Sputum specimens were subjected to smear, isolation, and culture. Culture-positive strains of bacteria were identified by bacterial groups. A total of 1659 strains of <i>Mycobacterium tuberculosis</i> (MTB) isolates were obtained. The drug susceptibility test was carried out using the proportionality method on the MTB isolates for nine types of antituberculosis medicines: isoniazid (INH), rifampicin (RFP), ethambutol (EMB), streptomycin (Sm), kanamycin (Km), ofloxacin (Ofx), capreomycin (Cm), propylthioisonicotinamide (Pto), and <i>p</i>-aminosalicylic acid (PAS). A comparative analysis of the resistance patterns among the strains was conducted.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 1659 patients with MTB were cultured, revealing 438 drug-resistant cases. Among these, 255 were monoresistant, 121 were polyresistant, and 62 were multidrug resistant. The overall resistance rate was 26.40% (438/1659), with mono-resistance rate at 15.37% (255/1659), polyresistance rate at 7.29% (121/1659), and multidrug resistance rate at 3.74% (62/1659). In descending order, the resistance rates of MTB isolates to any of the nine antituberculosis drugs were Sm (12.24%, 203/1659), INH (9.22%, 153/1659), EMB (7.35%, 122/1659), RFP (6.99%, 116/1659), PAS (3.25%, 54/1659), Pto (3.13%, 52/1659), Ofx (2.71%, 45/1659), Cm (2.17%, 36/1659), and Km (2.17%, 36/1659). The differences in resistance rates were statistically significant (<i>p</i> < 0.01), with Sm exhibiting the highest resistance rate and Km the lowest.</p>\n \n <p>In the primary treatment group, 388 patients (25.55%) were drug resistant, while 50 patients (35.46%) in the retreatment group were drug resistant. Thirty-nine patients (2.57%) in the primary treatment group were multidrug resistant, compared to 23 patients (16.31%) in the retreatment group. The resistance rate and multidrug resistance rate of isolates from retreatment patients were significantly higher than primary treatment patients (<i>p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The problem of drug-resistant tuberculosis transmission in Guangzhou requires attention, and drug-resistant screening should be further increased to effectively control the source of infection.</p>\n </section>\n </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"12 11","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70060","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity, Inflammation and Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iid3.70060","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The objectives of the study are to understand the drug-resistant situation and trend of tuberculosis patients in Yuexiu District, Guangzhou City, from 2013 to 2022, and to provide a scientific basis for the development of rational drug-resistant tuberculosis prevention and control strategies in Guangzhou City.

Methods

All patients who were diagnosed with active tuberculosis in Guangzhou Chest Hospital from January 1, 2013 to December 31, 2022 were collected as study subjects, and a total of 5191 patients were enrolled in the study. Comprehensive data on the basic characteristics, diagnostic, and therapeutic information of the study subjects were collected. Sputum specimens were subjected to smear, isolation, and culture. Culture-positive strains of bacteria were identified by bacterial groups. A total of 1659 strains of Mycobacterium tuberculosis (MTB) isolates were obtained. The drug susceptibility test was carried out using the proportionality method on the MTB isolates for nine types of antituberculosis medicines: isoniazid (INH), rifampicin (RFP), ethambutol (EMB), streptomycin (Sm), kanamycin (Km), ofloxacin (Ofx), capreomycin (Cm), propylthioisonicotinamide (Pto), and p-aminosalicylic acid (PAS). A comparative analysis of the resistance patterns among the strains was conducted.

Results

A total of 1659 patients with MTB were cultured, revealing 438 drug-resistant cases. Among these, 255 were monoresistant, 121 were polyresistant, and 62 were multidrug resistant. The overall resistance rate was 26.40% (438/1659), with mono-resistance rate at 15.37% (255/1659), polyresistance rate at 7.29% (121/1659), and multidrug resistance rate at 3.74% (62/1659). In descending order, the resistance rates of MTB isolates to any of the nine antituberculosis drugs were Sm (12.24%, 203/1659), INH (9.22%, 153/1659), EMB (7.35%, 122/1659), RFP (6.99%, 116/1659), PAS (3.25%, 54/1659), Pto (3.13%, 52/1659), Ofx (2.71%, 45/1659), Cm (2.17%, 36/1659), and Km (2.17%, 36/1659). The differences in resistance rates were statistically significant (p < 0.01), with Sm exhibiting the highest resistance rate and Km the lowest.

In the primary treatment group, 388 patients (25.55%) were drug resistant, while 50 patients (35.46%) in the retreatment group were drug resistant. Thirty-nine patients (2.57%) in the primary treatment group were multidrug resistant, compared to 23 patients (16.31%) in the retreatment group. The resistance rate and multidrug resistance rate of isolates from retreatment patients were significantly higher than primary treatment patients (p < 0.05).

Conclusions

The problem of drug-resistant tuberculosis transmission in Guangzhou requires attention, and drug-resistant screening should be further increased to effectively control the source of infection.

查看原文本刊更多论文

2013-2022年广州市越秀区结核病耐药性监测结果分析》。

引言本研究旨在了解广州市越秀区2013-2022年肺结核患者耐药情况及趋势，为广州市制定合理的耐药结核病防控策略提供科学依据：方法：收集 2013 年 1 月 1 日至 2022 年 12 月 31 日在广州市胸科医院确诊的活动性肺结核患者作为研究对象，共 5191 例。收集了研究对象的基本特征、诊断和治疗信息等全面数据。对痰标本进行涂片、分离和培养。培养阳性菌株按细菌组别进行鉴定。共获得 1659 株结核分枝杆菌（MTB）分离株。采用比例法对 MTB 分离菌株进行了九种抗结核药物的药敏试验：异烟肼（INH）、利福平（RFP）、乙胺丁醇（EMB）、链霉素（Sm）、卡那霉素（Km）、氧氟沙星（Ofx）、辣椒霉素（Cm）、丙硫异烟胺（Pto）和对氨基水杨酸（PAS）。对不同菌株的耐药性模式进行了比较分析：结果：共培养出 1659 例 MTB 患者，发现 438 例耐药病例。其中，255 例为单耐药，121 例为多耐药，62 例为耐多药。总耐药率为 26.40%（438/1659），单耐药率为 15.37%（255/1659），多耐药率为 7.29%（121/1659），耐多药率为 3.74%（62/1659）。MTB分离株对9种抗结核药物中任何一种的耐药率从高到低依次为Sm（12.24%，203/1659）、INH（9.22%，153/1659）、EMB（7.35%，122/1659）、RFP（6.99%，116/1659）、PAS（3.25%，54/1659）、Pto（3.13%，52/1659）、Ofx（2.71%，45/1659）、Cm（2.17%，36/1659）和 Km（2.17%，36/1659）。耐药率的差异具有显著的统计学意义（P 结论：耐药率的差异具有显著的统计学意义（P 结论：耐药率的差异具有显著的统计学意义（P））：广州市耐药结核病传播问题需引起重视，应进一步加大耐药筛查力度，有效控制传染源。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunity, Inflammation and Disease Medicine-Immunology and Allergy

CiteScore

3.60

自引率

0.00%

发文量

146

审稿时长

8 weeks

期刊介绍： Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal is indexed in Medline and the Science Citation Index Expanded (part of Web of Science), among others. It welcomes original work that enhances the understanding of immunology in areas including: • cellular and molecular immunology • clinical immunology • allergy • immunochemistry • immunogenetics • immune signalling • immune development • imaging • mathematical modelling • autoimmunity • transplantation immunology • cancer immunology